ADVM — Adverum Biotechnologies Share News
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)
Eli Lilly to buy gene therapy developer Adverum in about $262 million deal
Brief: Lilly To Acquire Adverum Biotechnologies
Brief: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Adverum Biotechnologies Inc reports results for the quarter ended June 30 - Earnings Summary
Adverum Biotechnologies Inc expected to post a loss of $2.25 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Alphabet, Booking Holdings, Meta
Adverum Biotechnologies Inc expected to post a loss of $1.81 a share - Earnings Preview
Adverum Biotechnologies Inc expected to post a loss of $1.94 a share - Earnings Preview
Adverum Biotechnologies Inc reports results for the quarter ended December 31 - Earnings Summary
Advisory: Alert on Adverum Biotechnologies from press release by law firm withdrawn
U.S. RESEARCH ROUNDUP- BlackRock, Morgan Stanley, ServiceNow
Brief: Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Adverum Biotechnologies Inc expected to post a loss of $1.36 a share - Earnings Preview
Brief: Adverum Biotechnologies Inc - Some Prior Financial Statements Should No Longer Be Relied Upon - SEC Filing
Adverum Biotechnologies Inc expected to post a loss of $1.36 a share - Earnings Preview